Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Paranasal Sinuses | 4 | 2023 | 66 | 2.590 |
Why?
|
| Nasal Surgical Procedures | 3 | 2023 | 5 | 2.390 |
Why?
|
| Tranexamic Acid | 2 | 2023 | 40 | 1.660 |
Why?
|
| Endoscopy | 4 | 2023 | 247 | 1.410 |
Why?
|
| Lymphatic Abnormalities | 2 | 2020 | 18 | 1.300 |
Why?
|
| Nasal Obstruction | 3 | 2022 | 22 | 1.150 |
Why?
|
| Nose Diseases | 2 | 2021 | 11 | 0.970 |
Why?
|
| Antifibrinolytic Agents | 1 | 2023 | 50 | 0.810 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2022 | 10 | 0.800 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 33 | 0.700 |
Why?
|
| Neck | 1 | 2020 | 84 | 0.690 |
Why?
|
| Hydrocodone | 1 | 2018 | 15 | 0.650 |
Why?
|
| Dyspnea | 1 | 2020 | 223 | 0.630 |
Why?
|
| Mesothelioma | 2 | 2015 | 31 | 0.620 |
Why?
|
| Postoperative Complications | 2 | 2020 | 2161 | 0.620 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 215 | 0.610 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 195 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 254 | 0.570 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 250 | 0.550 |
Why?
|
| Inpatients | 1 | 2020 | 380 | 0.550 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 526 | 0.540 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 323 | 0.540 |
Why?
|
| Acetaminophen | 1 | 2018 | 237 | 0.530 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 301 | 0.530 |
Why?
|
| Pleural Neoplasms | 1 | 2015 | 18 | 0.510 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 344 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 336 | 0.490 |
Why?
|
| Olfaction Disorders | 2 | 2023 | 48 | 0.420 |
Why?
|
| Epistaxis | 2 | 2023 | 11 | 0.420 |
Why?
|
| Rhinitis | 3 | 2023 | 128 | 0.420 |
Why?
|
| Turbinates | 2 | 2022 | 11 | 0.400 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 783 | 0.380 |
Why?
|
| Telemedicine | 1 | 2018 | 667 | 0.360 |
Why?
|
| Humans | 18 | 2023 | 115589 | 0.240 |
Why?
|
| Sinusitis | 2 | 2023 | 175 | 0.240 |
Why?
|
| Smell | 2 | 2022 | 113 | 0.240 |
Why?
|
| Quality of Life | 4 | 2023 | 2385 | 0.240 |
Why?
|
| Cystic Fibrosis | 2 | 2023 | 957 | 0.230 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2023 | 10 | 0.230 |
Why?
|
| Benzodioxoles | 1 | 2023 | 83 | 0.210 |
Why?
|
| Platelet-Rich Plasma | 1 | 2022 | 23 | 0.210 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 2207 | 0.210 |
Why?
|
| Aminophenols | 1 | 2023 | 112 | 0.210 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 86 | 0.210 |
Why?
|
| Drug Combinations | 2 | 2023 | 289 | 0.200 |
Why?
|
| Cautery | 1 | 2022 | 3 | 0.200 |
Why?
|
| Indoles | 1 | 2023 | 309 | 0.190 |
Why?
|
| Bevacizumab | 1 | 2022 | 118 | 0.190 |
Why?
|
| Vibration | 1 | 2021 | 61 | 0.190 |
Why?
|
| Nasal Cavity | 1 | 2021 | 47 | 0.190 |
Why?
|
| Rhinoplasty | 1 | 2021 | 23 | 0.190 |
Why?
|
| Seroma | 1 | 2020 | 3 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2023 | 9159 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 503 | 0.160 |
Why?
|
| Return to Work | 1 | 2018 | 20 | 0.160 |
Why?
|
| Visual Analog Scale | 1 | 2018 | 30 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2020 | 12608 | 0.160 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1659 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 260 | 0.160 |
Why?
|
| Operative Time | 1 | 2018 | 109 | 0.150 |
Why?
|
| Tumor Burden | 2 | 2015 | 261 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2023 | 6264 | 0.150 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 127 | 0.140 |
Why?
|
| Male | 7 | 2023 | 55949 | 0.140 |
Why?
|
| Female | 7 | 2023 | 59913 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1216 | 0.130 |
Why?
|
| Child, Preschool | 2 | 2020 | 9133 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 85 | 0.120 |
Why?
|
| Middle Aged | 5 | 2023 | 26998 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 284 | 0.110 |
Why?
|
| Length of Stay | 1 | 2018 | 958 | 0.110 |
Why?
|
| Mentors | 1 | 2014 | 162 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2014 | 211 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1334 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2014 | 174 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 4440 | 0.100 |
Why?
|
| Child | 2 | 2020 | 18489 | 0.090 |
Why?
|
| Time Factors | 1 | 2020 | 6165 | 0.090 |
Why?
|
| Students, Medical | 1 | 2014 | 277 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2392 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2023 | 1598 | 0.070 |
Why?
|
| Adult | 4 | 2023 | 30719 | 0.070 |
Why?
|
| Aged | 3 | 2021 | 19250 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2014 | 912 | 0.070 |
Why?
|
| Infant | 1 | 2020 | 7979 | 0.070 |
Why?
|
| Risk Factors | 1 | 2020 | 8697 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 4665 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2023 | 56 | 0.060 |
Why?
|
| Quinolones | 1 | 2023 | 97 | 0.050 |
Why?
|
| Adolescent | 1 | 2020 | 17890 | 0.050 |
Why?
|
| Nose | 1 | 2022 | 56 | 0.050 |
Why?
|
| Patient Health Questionnaire | 1 | 2021 | 20 | 0.050 |
Why?
|
| Ribs | 1 | 2021 | 29 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2023 | 362 | 0.050 |
Why?
|
| Pyridines | 1 | 2023 | 425 | 0.040 |
Why?
|
| Syndrome | 1 | 2021 | 339 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 292 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2022 | 257 | 0.040 |
Why?
|
| Cadaver | 1 | 2021 | 316 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 532 | 0.040 |
Why?
|
| Cartilage | 1 | 2021 | 182 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6417 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 276 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 32102 | 0.030 |
Why?
|
| Volunteers | 1 | 2014 | 31 | 0.030 |
Why?
|
| Peer Group | 1 | 2014 | 206 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1178 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2014 | 342 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2014 | 836 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1856 | 0.020 |
Why?
|
| Young Adult | 1 | 2023 | 10470 | 0.020 |
Why?
|